Earnings ·
SeaStar Medical Holding Corporation reported financial results for the second quarter ended June 30, 2026
ICUCWSeaStar Medical Holding Corp
SeaStar Medical Holding Corporation reported financial results for the second quarter ended June 30, 2026. Net revenue increased 82% to $0.6 million from $0.3 million in the prior year period, driven by QUELIMMUNE product sales. The company incurred a net loss of $3.7 million, or $0.91 per share, compared to a $2.0 million loss in the same quarter last year. Cash reserves declined to $7.0 million from $12.0 million at year-end 2025. Research and development expenses rose to $2.5 million due to clinical trial costs, while general and administrative expenses increased to $1.8 million. The company added three new pediatric hospital customers for its QUELIMMUNE therapy and advanced enrollment in the NEUTRALIZE-AKI pivotal trial to 223 of 339 patients. CMS issued dedicated ICD-10-PCS codes for SCD therapy, effective October 1, 2026. SeaStar Medical is a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure.